Corcept Therapeutics Incorporated
CORT
$57.08
$5.9211.57%
NASDAQ
| 03/31/2026 | 12/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -18.42% | -2.66% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -18.42% | -2.66% | |||
| Cost of Revenue | 13.28% | -44.63% | |||
| Gross Profit | -18.82% | -1.71% | |||
| SG&A Expenses | 11.61% | 5.05% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 8.53% | 0.11% | |||
| Operating Income | -1,205.44% | -56.09% | |||
| Income Before Tax | -551.21% | -34.99% | |||
| Income Tax Expenses | 9.90% | -224.93% | |||
| Earnings from Continuing Operations | -230.77% | 23.49% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -230.77% | 23.49% | |||
| EBIT | -1,205.44% | -56.09% | |||
| EBITDA | -1,126.03% | -54.55% | |||
| EPS Basic | -229.63% | 23.26% | |||
| Normalized Basic EPS | -548.24% | -35.11% | |||
| EPS Diluted | -249.78% | 25.19% | |||
| Normalized Diluted EPS | -617.60% | -35.21% | |||
| Average Basic Shares Outstanding | 0.71% | 0.14% | |||
| Average Diluted Shares Outstanding | -12.87% | 0.35% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||